Hemostemix Inc. (HMTXF)
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The firm's, ACP-01, lead clinical stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. The company was founded by Roger Bergersen and Thomas A. Smeenk in 2006 and is headquartered in Calgary, Canada.
Sector: Biotechnology
Industry: Biotechnology
OTC:HMTXF
As of the Oct 30, 2026 FINRA settlement, 45,000 HMTXF shares were sold short (0.03% of a 168.41M-share float, 19.04 days to cover).